Evidence map›Paper›PMID 21607646›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2011

Understanding protein kinase CK2 mis-regulation upon F508del CFTR expression.

Andrea Venerando, Mario A Pagano, Kendra Tosoni, Flavio Meggio, Diane Cassidy, Michelle Stobbart, Lorenzo A Pinna, Anil Mehta

Open access · hybridAbstract readReview
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. CFTR mutations altering CFTR fragmentation.The Biochemical journal · 2013
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Andrea VenerandoDepartment of Biological Chemistry and CNR Institute of Neurosciences, University of Padova, viale G. Colombo 3, 35131, Padua, Italy.
Mario A Pagano
Kendra Tosoni
Flavio Meggio
Diane Cassidy
Michelle Stobbart
Lorenzo A Pinna
Anil Mehta
University of Padua · ITUniversity of Dundee · GBNinewells Hospital · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

We review areas of overlap between nucleoside diphosphate kinase (NDPK; nm23) and two proteins manifesting an equivalent diversity of action, each with many thousands of publications. The first is a constitutively active protein kinase, CK2 (formerly casein kinase 2), that includes NDPK amongst its hundreds of targets. The second is an enigmatic member of the ATP-binding cassette (ABC) family of membrane pumps that normally hydrolyse ATP to transport substrates. Yet our unusual family member (ABCC7) is not a pump but, uniquely, acts as a regulated anion channel. ABCC7 is the cystic fibrosis transmembrane conductance regulator (CFTR), and we discuss the highly prevalent CFTR mutation (F508del CFTR) in terms of the uncertainties surrounding the molecular basis of cystic fibrosis that cloud approaches to corrective therapy. Using lysates from cells stably expressing either wild-type or F508del CFTR, incubated with the CK2 substrate GTP, we show that the phosphoproteome of F508del CFTR-expressing cells both differs from wild-type CFTR-expressing cells and is significantly enhanced in intensity by ∼1.5-fold (p < 0.05, paired t test with Bonferroni correction, n = 4). Phosphorylation is about 50% attenuated with a specific CK2 inhibitor. We propose that a new function may exist for the CFTR region that is commonly mutated, noting that its sequence (PGTIKENIIF(508)GVSYDEYRYR) is not only highly conserved within the C sub-family of ABC proteins but also a related sequence is found in NDPK. We conclude that a latent path may exist between mutation of this conserved sequence, CK2 hyperactivity and disease pathogenesis that might also explain the heterozygote advantage for the common F508del CFTR mutant.

Indexed as

Cystic FibrosisAnimalsBlotting, WesternCasein Kinase IICell Line, TumorCricetinaeCystic Fibrosis Transmembrane Conductance RegulatorElectrophoresis, Gel, Two-DimensionalHumansNM23 Nucleoside Diphosphate KinasesPhosphorylationSignal TransductionTransfectionCasein Kinase IICystic Fibrosis Transmembrane Conductance Regulatorcystic fibrosis transmembrane conductance regulator delta F508NM23 Nucleoside Diphosphate Kinases

Identifiers

PMID21607646
PMCPMC3208816
OpenAlexW2061602784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.